"The increasing expenses associated with bladder cancer treatment highlight wider issues regarding the sustainability of health care expenditures in the US," writes Michael S. Cookson, MD, MMHC, FACS.

“Our findings highlight the coordinated interplay between GCN2 and p53 regulation during nutrient stress and provide insight into how they could be targeted in developing new therapeutic strategies ...

Sasanlimab combined with BCG significantly improved event-free survival in BCG-naïve, high-risk NMIBC patients compared to BCG alone. The CREST trial's results suggest potential paradigm shifts in ...

A panelist discusses how identifying intermediate-risk patients, managing disease heterogeneity in non–muscle-invasive bladder cancer, and addressing long-term care needs present key challenges in ...

A panelist discusses how emerging investigational agents for NMIBC show promise through diverse mechanisms, including oncolytic viruses (CG0070), immune checkpoint inhibitors (durvalumab, sasanlimab), ...

“Another aspect is how to make this more and more complex diagnostic chain for prostate cancer work in practice, because we now have so [many] more tools than we had a decade ago,” says Tobias ...

The test can provide results in 48 minutes to provide diagnostic insights for conditions such as hypogonadism, impotence, polycystic ovarian syndrome, and other androgenital syndromes.

“As long as APPs are properly supported, they will take off and they will change your practice,” says Mark T. Edney, MD. In this video, Mark T. Edney, MD, discusses how to foster a collaborative ...

VIR-5500 demonstrated promising PSA response in mCRPC patients, with 58% achieving at least a 50% reduction in PSA levels. No dose-limiting toxicities were observed, and treatment-emergent adverse ...

TYRA-300's phase 2 trial in NMIBC aims to evaluate safety and efficacy, enrolling up to 90 patients with FGFR3 alterations. The primary endpoint is the complete response rate at 3 months, with ...

As the year comes to a close, we revisit some of this year’s top content on next-generation imaging agents in urology. The trial is evaluating the diagnostic performance of copper Cu 64 PSMA I&T ...

A full market release of the HYDROS System is expected within the current quarter.